Moreover, an apparent good novelty is the body of data that suggests that the BTK and PI3K inhibitors, which are currently in use to treat the disease, are also effective on the tumor microenvironment, additionally limiting the disease-associated bone lesions. The gene discussed is BTK; the disease is neoplasm.